Literature DB >> 23376021

Long-lasting changes in hippocampal synaptic plasticity and cognition in an animal model of NMDA receptor dysfunction in psychosis.

Valentina Wiescholleck1, Denise Manahan-Vaughan.   

Abstract

It is postulated that disruptions of glutamatergic signalling may underlie the pathophysiology of psychosis and schizophrenia. A strong body of evidence indicates that antagonism of the N-methyl-d-aspartate receptor (NMDAR) leads to similar molecular, cellular, cognitive and behavioural changes in rodents and/or humans to those that have been identified to occur in psychosis. One of the main loci of change appears to comprise the hippocampus, raising the question as to whether changes in hippocampal glutamatergic transmission may drive changes in GABAergic and dopaminergic-mediated signalling in schizophreniform diseases. NMDAR antagonists such as MK801, PCP and ketamine all elicit similar psychosis-related effects, with MK801 inducing the most potent psychotomimetic reactions. Treatment with MK801 is associated with a loss of hippocampal synaptic plasticity, hippocampus-dependent learning and cognitive deficits. These findings have raised the question as to whether targeting the NMDA receptors or its modulators could prove an effective strategy in treatment of psychosis and schizophrenia. Specifically, the otherwise untreatable negative and cognitive symptoms of schizophrenia currently comprise the highest research priority. A single injection with MK801 has been used to emulate first-episode psychosis in animals. This treatment induces both psychosis-related acute effects but interestingly also persisting consequences, which might be more sensitive as indicators of drug efficacy. Here, we review the current status of the field with regard to the MK801 animal model of first-episode psychosis and its relevance for the glutamate hypothesis of schizophrenia. Furthermore, we argue that synaptic plasticity may be a better assay for assessing novel schizophrenia therapeutics than behavioural evaluation. This article is part of the Special Issue entitled 'Glutamate Receptor-Dependent Synaptic Plasticity'.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Animal model; Dizocilpine; Hippocampus; LTP; MK801; Psychosis; Schizophrenia

Mesh:

Substances:

Year:  2013        PMID: 23376021     DOI: 10.1016/j.neuropharm.2013.01.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  17 in total

1.  Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.

Authors:  Toshihiro Nomura; Yoshihiro Oyamada; Herman B Fernandes; Christine L Remmers; Jian Xu; Herbert Y Meltzer; Anis Contractor
Journal:  Neuropharmacology       Date:  2015-04-30       Impact factor: 5.250

2.  Ketamine: NMDA Receptors and Beyond.

Authors:  Charles F Zorumski; Yukitoshi Izumi; Steven Mennerick
Journal:  J Neurosci       Date:  2016-11-02       Impact factor: 6.167

3.  Preliminary analysis of positive and negative syndrome scale in ketamine-associated psychosis in comparison with schizophrenia.

Authors:  Ke Xu; John H Krystal; Yuping Ning; Da Chun Chen; Hongbo He; Daping Wang; Xiaoyin Ke; Xifan Zhang; Yi Ding; Yuping Liu; Ralitza Gueorguieva; Zuoheng Wang; Diana Limoncelli; Robert H Pietrzak; Ismene L Petrakis; Xiangyang Zhang; Ni Fan
Journal:  J Psychiatr Res       Date:  2014-12-24       Impact factor: 4.791

Review 4.  The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Authors:  Samuel M Cohen; Richard W Tsien; Donald C Goff; Michael M Halassa
Journal:  Schizophr Res       Date:  2015-01-09       Impact factor: 4.939

5.  Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice.

Authors:  Shunsuke Takagi; Darrick T Balu; Joseph T Coyle
Journal:  Schizophr Res       Date:  2015-01-12       Impact factor: 4.939

6.  Altered neuronal excitability underlies impaired hippocampal function in an animal model of psychosis.

Authors:  Thomas Grüter; Valentina Wiescholleck; Valentyna Dubovyk; Verena Aliane; Denise Manahan-Vaughan
Journal:  Front Behav Neurosci       Date:  2015-05-20       Impact factor: 3.558

7.  Meta gene set enrichment analyses link miR-137-regulated pathways with schizophrenia risk.

Authors:  Carrie Wright; Vince D Calhoun; Stefan Ehrlich; Lei Wang; Jessica A Turner; Nora I Perrone- Bizzozero
Journal:  Front Genet       Date:  2015-04-20       Impact factor: 4.599

8.  Abnormal Motor Activity and Thermoregulation in a Schizophrenia Rat Model for Translational Science.

Authors:  Gyongyi Horvath; Gabriella Kekesi; Zita Petrovszki; Gyorgy Benedek
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

Review 9.  Autoantibodies to neurotransmitter receptors and ion channels: from neuromuscular to neuropsychiatric disorders.

Authors:  Pilar Martinez-Martinez; Peter C Molenaar; Mario Losen; Jo Stevens; Marc H De Baets; Andrei Szoke; Jerome Honnorat; Ryad Tamouza; Marion Leboyer; Jim Van Os; Bart P F Rutten
Journal:  Front Genet       Date:  2013-09-20       Impact factor: 4.599

10.  Nerve growth factor and its receptor in schizophrenia.

Authors:  Roksana Zakharyan; Sofi Atshemyan; Anaida Gevorgyan; Anna Boyajyan
Journal:  BBA Clin       Date:  2014-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.